ADIPOQ and type 2 diabetes mellitus: In an animal experiment on Olmesartan [109], it was demonstrated that Olmesartan inhibits the expression of AGE/RAGE/p-JNK pathways while increasing the PPARγ/ADPN pathway, thereby alleviating the symptoms of liver injury in patients with type 2 diabetes mellitus.